ArticleAntibiotics (Basel, Switzerland)2022
Polyclonal Endemicity of Carbapenemase-Producing
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- A Seven-Year Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Environmental contamination of carbapenem-resistant gram-negative bacteria away from isolated patients in intensive care unit: a comprehensive surveillance study.Scientific reports · 2025Article
- Genomic and Phenotypic Characterization of Two High-RiskAntibiotics (Basel, Switzerland) · 2025Article
- Detection ofMicroorganisms · 2025Article
- Report of High-Risk Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Rapid Reversal of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Assessment of in vitro activity of ceftazidime/avibactam on carbapenemase-producingHealth science reports · 2024Article
- Molecular characterization and epidemiological investigation of colistin resistance in carbapenem-resistant Klebsiella pneumoniae in a tertiary care hospital in Tehran, Iran.BMC microbiology · 2024Article
- Incidence, risk factors and clinical outcome of multidrug-resistant organisms after heart transplantation.World journal of transplantation · 2024Article
- Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species andAntibiotics (Basel, Switzerland) · 2024Review
- Development and application of a nomogram model for the prediction of carbapenem-resistantMicrobiology spectrum · 2024Article
- Epidemiology and Resistance Phenotypes of Carbapenem-ResistantMicroorganisms · 2023Article
- High prevalence of OXA-48-like and NDM carbapenemases among carbapenem resistantIranian journal of microbiology · 2023Article
- Neonatal Bloodstream Infection with Ceftazidime-Avibactam-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Probable Three-Species In Vivo Transfer ofAntibiotics (Basel, Switzerland) · 2023Article
- Mortality due to Multidrug-Resistant Gram-Negative Bacteremia in an Endemic Region: No Better than a Toss of a Coin.Microorganisms · 2023Article
- New Bacteriophages Members of thePHAGE (New Rochelle, N.Y.) · 2023Article
- Genetic Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Replacement of the Double Meropenem Disc Test with a Lateral Flow Assay for the Detection of Carbapenemase-Producing Enterobacterales andAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.